Screener
Biogen BIIB AOCI
AOCI at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Biogen’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 6:36 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000875045-26-000075
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Preferred stock, par value $0.001 per share | — | — |
| Common stock, par value $0.0005 per share | 0.1 | 0.1 |
| Additional paid-in capital | 983.0 | 863.1 |
| Accumulated other comprehensive income (loss) | (127.7) | (182.0) |
| Retained earnings | 20,969.7 | 20,552.7 |
| Treasury stock, at cost | (2,977.1) | (2,977.1) |
| Total equity | 18,848.0 | 18,256.8 |
| Total liabilities and equity | $32,086.6 | $29,439.5 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Biogen's AOCI?
- Biogen (BIIB) reported AOCI of -$127.7M in Q2 2026.
- How has Biogen's AOCI changed year-over-year?
- Biogen's AOCI increased by 46.4% year-over-year, from -$238.1M to -$127.7M.
- What is the long-term trend for Biogen's AOCI?
- Over 5 years (2020 to 2025), Biogen's AOCI has grown at a -9.5% compound annual growth rate (CAGR), from -$299M to -$182M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Biogen's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude